Produced as a tissue defence response to hypoxia and inflammation, growth differentiation factor-15 (GDF-15) is elevated in people receiving metformin treatment. To gain insight into the relationship of GDF-15 with metformin and major cardiovascular risk factors, we analysed the data from the SUMMIT cohort (n = 1438), a four-centre, nested, case-control study aimed at verifying whether biomarkers of atherosclerosis differ according to the presence of type 2 diabetes and cardiovascular disease. While in univariate analysis, major cardiovascular risk factors, with the exception of gender and cholesterol, increased similarly and linearly across GDF-15 quartiles, the independent variables associated with GDF-15, both in participants with and without diabetes, were age, plasma creatinine, N-terminal pro-brain natriuretic peptide, diuretic use, smoking exposure and glycated haemoglobin. In participants with diabetes, metformin treatment was associated with a 40% rise in GDF-15 level, which was independent of the other major factors, and largely explained their elevated GDF-15 levels. The relatively high GDF-15 bioavailability might partly explain the protective cardiovascular effects of metformin. 
| MATERIALS AND METHODS

| Study population
Volunteers for the present study were recruited from patients, and their relatives, attending the four outpatient clinics for metabolic dis- 
| Data and statistical analysis
The participants were divided according to the presence of T2D, and quartiles of plasma levels of GDF-15 were calculated within each group. Differences across quartiles of GDF-15 were investigated using either the chi-squared or Wilcoxon statistics for frequency or continuous values, respectively. P values ≤0.05 were taken to indicate statistical significance. Multiple regression analysis was conducted according to the restricted maximum likelihood method using a random effect attribute for the variable centre. The strength of the associations was quantified by the logWorth value.
3 | RESULTS
| Study population
The study cohort consisted of 1438 volunteers (937 men and 501 women, aged 42-88 years), recruited at the four centres within the SUMMIT multicentre study (with available GDF-15 data);
448 participantts had T2D and clinically manifest CVD, 495 participants had T2D without clinical history or evidence of CVD, 238 participants had CVD but no T2D, and 257 participants had neither CVD nor T2D.
| GDF-15 and clinical data
The median (interquartile range) approximate plasma GDF-15 concentrations were higher in the presence of CVD or T2D, either alone (Table S1 ). Higher GDF-15 levels were associated, in a quasi-linear fashion in both study groups, with older age, prevalence of hypertension, history or evidence of major atherosclerotic CVD, smoking exposure, and systolic blood pressure, while neither gender nor body mass index were different (Table S1 ). With regard to the ongoing treatments, diuretics and renin-angiotensin system blockers increased across quartiles in both groups and, among the participants with T2D, higher GDF-15 values were associated also with a lower prevalence of diet treatment only and greater use of each and all plasma-lowering drugs (metformin, sulphonylureas, dipeptidyl peptidase-4 inhibitors and insulin).
| GDF-15 and biochemical variables
Among the biochemical variables (Table S2) , GDF-15 was associated in both study groups with higher levels of creatinine, NT-proBNP and glycated haemoglobin (HbA1c); however, we observed an inverse trend with total LDL and HDL cholesterol, which was coupled with higher rates of ongoing statin therapy. No trend was found with plasma triglycerides in either group. Table 1 shows the clinical and the biochemical variables that were found to have a statistically significant and independent relationship with GDF-15 in multivariate analysis, separately for participants with and without T2D and in the whole population (with T2D entered as a dummy variable). In participants without T2D the variables more strongly associated with GDF-15 were: NT-proBNP; age; serum creatinine; smoking exposure; diuretic use; and HbA1c, in that order. In participants with T2D, the strongest association was observed with ongoing metformin treatment, followed by serum creatinine, NTproBNP, age, HbA1c, diuretic treatment and smoking exposure, in that order. In participants with T2D receiving metformin (n = 644), the median (interquartile range) approximate absolute plasma GDF-15 levels were twice as high as in participants without diabetes 
| Multivariate analysis
| DISCUSSION
Our data confirm that the plasma GDF-15 level is raised in the presence of each and all the major risk factors for atherosclerotic CVD, with the exception of plasma LDL cholesterol. Although still observed after adjusting for ongoing statin therapy, the achieved LDL cholesterol levels are likely to inversely reflect the overall cardiovascular risk of the patients. We also showed that metformin use was associated with elevated GDF-15 plasma levels and demonstrated that its contribution largely explains the consistent finding of increased plasma GDF-15 levels in T2D. 8 When all the relevant variables were entered into a multivariate model, a similar pattern was observed in both study groups and in the whole cohort, with NT-proBNP, age and serum creatinine emerging as the strongest predictors ( Table 1 ). The major difference was in the strength of the association with metformin in participants with T2D, which was much greater than and also independent of any other variable, being responsible for a 40% rise in GDF-15 level. Interestingly, HbA1c, although with a smaller effect, was associated with higher GDF-15 levels in both participants with T2D and those without T2D, and this is a novel finding. Notably, this association was lost in the participants on metformin treatment (β = 0.003 AE 0.002), while it One possible explanation for the association of GDF-15 with metformin treatment, and also with HbA1c, could be that this growth factor is also a powerful marker of presence and severity of mitochondrial disorders 11 and/or hypoxia. 3 In fact, both metformin and hyperglycaemia are known to interfere with mitochondrial bioenergetics.
Moreover, high glucose in human umbilical endothelial cells 5 
and in
HepG2 cells 12 is able to promote GDF-15 expression and secretion, and, in participants without diabetes, glucose ingestion is associated with an elevation of plasma GDF-15 levels. 13 The results of the present study confirm that current smoking is associated with elevated GDF-15, 14 but the association with smoking exposure was stronger than with current smoking status; therefore, we suggest that it is chronic damage to pulmonary structures 15 that results in a persistent GDF-15 upregulation. Similarly, as circulating GDF-15 levels are strongly correlated with its intra-renal expression, 16 we interpret the association with plasma creatinine as a reflection of chronic kidney damage.
We acknowledge that the present study cohort had particular characteristics and therefore our conclusions cannot be extended to the general population; however, the inclusion of participants with CVD and risk factors offered the opportunity to explore the full range of pathophysiological characteristics related to CVD. Clearly, the present analysis was cross-sectional and the participants were treated with an intensity that would be expected to be proportional to the severity of their diseases. While this might have hampered our ability to detect the relevance of GDF-15 in the natural context of each atherosclerosis-related disease/condition, it also represented an opportunity to gain information on real-world outpatients with regard to residual and unexplained CVD risk.
